0001213900-21-059358.txt : 20211115 0001213900-21-059358.hdr.sgml : 20211115 20211115161027 ACCESSION NUMBER: 0001213900-21-059358 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211115 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virpax Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001708331 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821510982 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40064 FILM NUMBER: 211410599 BUSINESS ADDRESS: STREET 1: 1554 PAOLI PIKE #279 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-875-3195 MAIL ADDRESS: STREET 1: 1554 PAOLI PIKE #279 CITY: WEST CHESTER STATE: PA ZIP: 19380 FORMER COMPANY: FORMER CONFORMED NAME: Virpax Pharmaceuticals Inc. DATE OF NAME CHANGE: 20170602 8-K 1 ea150252-8k_virpaxpharma.htm CURRENT REPORT
0001708331 false 0001708331 2021-11-15 2021-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2021

 

Virpax Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40064   82-1510982

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of principal executive offices, including zip code)

 

(610) 727-4597

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Trading Symbol   Name of Each Exchange on which Registered
Common Stock, par value $0.00001 per share   VRPX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

Virpax Pharmaceuticals, Inc. (the “Company”) issued a press release on November 15, 2021, disclosing financial information and operating metrics for the third quarter ended September 30, 2021, and providing a corporate update. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 7.01 Regulation FD Disclosure.

 

See “Item 2.02 Results of Operation and Financial Condition” above.

 

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by a specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

  

Description

99.1   Press release of Virpax Pharmaceuticals, Inc. issued November 15, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIRPAX PHARMACEUTICALS, INC.
     
Dated: November 15, 2021 By: /s/ Christopher Chipman
    Christopher Chipman
    Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea150252ex99-1_virpaxpharma.htm PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC. ISSUED NOVEMBER 15, 2021

Exhibit 99.1

 

Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments

 

--Company Strengthens Balance Sheet to Advance Product Pipeline--

 

BERWYN, PA --Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments.

 

“We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. We recently raised $40 million in an underwritten public offering of our common stock which greatly strengthened our balance sheet and has allowed us to accelerate our development timelines related to our non-clinical studies. Our goal is to successfully complete our Investigational New Drug (IND) filings and begin first-in-human trials as soon as possible,” stated Anthony Mack, chairman and CEO of Virpax.

 

“With our cash on hand of $41.7 million as of September 30, 2021, we believe we have sufficient funds to advance our 505(b)(2) product candidates, Epoladerm™ and Probudur™, through to a New Drug Application(NDA) filing. For Epoladerm, our spray film product candidate, based on our non-clinical studies and research we believe that osteoarthritis of the knee is a better global market opportunity for the Company and will focus our efforts for Epoladerm on this indication. With Probudur, our injectable bupivacaine liposomal hydrogel for postoperative pain management, we are working on improving the formulation to increase stability so that manufacturing would be less complex. We also anticipate being able to extend the patent protection for this product candidate.

 

“Our current remaining product pipeline leverages our licensed Molecular Envelope Technology (MET) which delivers medication through an intranasal delivery device that both permeates the blood-brain barrier and may bypass the liver. Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS). We recently announced that under this CRADA, the National Institutes of Health has awarded multiple contracts to support the development and manufacturing of Envelta. We are looking forward to the completion of the required IND enabling studies and submitting our IND package to the FDA in anticipation of first-in-human trials,” continued Mr. Mack.

 

“Through ongoing work with our MET platform, we discovered that our product candidate, AnQlar™, may provide a molecular barrier to respiratory infections such as SARS-CoV-2 and influenza by binding to the surface of viruses which in turn prevents the virus from binding to cell surface receptors that mediate viral infection. Following the receipt of a written pre-IND response from the FDA, our plan for AnQlar is to complete all studies required for an NDA submission as an over-the-counter (OTC) product. We believe there is a very large market for AnQlar and we are developing this product candidate to be used as a once daily intranasal administration to inhibit the ability of viruses to replicate and prevent viral spread.

 

“Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. VRP324 utilizes our novel MET intranasal delivery platform which, based on our early research, may bypass the liver and alleviate concerns related to drug-to-drug interaction compared to the currently available oral dosed cannabidiol product approved to manage seizure disorders.

 

 

 

 

“This is an exciting time at Virpax, and we believe that all of our product candidates have the potential to deliver significant improvements and benefits to currently existing treatment options,” concluded Mr. Mack.

 

RECENT DEVELOPMENTS

 

●On July 30, 2021, Virpax announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors.
●On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar. The FDA has indicated that Virpax may pursue an NDA drug approval with the Office of Non-Prescription Drugs. The Company is developing this product candidate as a prophylactic treatment against SARS and influenza and has engaged Syneos Health to assist with the optimal clinical trial design.
●On September 9, 2021, Jeffrey A. Gudin, MD, Chief Medical Officer of Virpax, presented a poster on Leucine Enkephalin as a potential analgesic at PainWeek 2021 in Las Vegas, Nevada.
●On September 16, 2021, Virpax closed an underwritten public offering of 6,670,000 shares of its common stock for gross proceeds of $40,020,000 before the deduction of underwriting discounts and offering expenses. The Company intends to use substantially all of the net proceeds from the underwritten offering to fund research and development of all of its product candidates and other development programs and for working capital and other general corporate purposes.
●On September 20, 2021, Virpax announced that it had acquired the exclusive worldwide rights from Nanomerics Ltd., for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 is being developed to treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome, and Dravet syndrome in patients one year of age and older.
●On October 6, 2021, Virpax announced an agreement with Sinclair Research to initiate IND enabling studies for AnQlar as a daily OTC prophylactic for treatment against SARS and influenza. Sinclair is expected to begin the preclinical animal studies at the beginning of 2022 as part of the enabling trials for an IND application with the FDA.

 

SCIENTIFIC ACHIEVEMENTS

 

●On June 21, 2021, Virpax announced that the IND enabling studies for Envelta being performed under a Cooperative Research and Development Agreement entered into by Virpax and NCATS for acute and chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic Stress Disorder. NCATS has commenced the IND enabling studies of Envelta to support Virpax’s future application for clearance from the FDA to initiate Virpax’s first-in-human clinical trials. The Company believes the same Phase I Single Ascending Dose /Multiple Ascending Dose study could be used to advance all three indications.

 

FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

 

Three Months Ended September 30, 2021 and 2020

 

Operating Expenses

 

General and administrative expenses increased by $0.7 million, or 91%, to $1.6 million for the three months ended September 30, 2021, from $0.8 million for the three months ended September 30, 2020. The primary reasons for the increase in general and administrative costs were (i) an increase in legal costs associated with litigation efforts and general corporate purposes of $0.6 million, (ii) an increase in insurance costs related to directors’ and officers’ insurance of $0.3 million, (iii) an increase in salaries and wages of $0.1 million attributable to new hires, and (iv) an increase in grant consulting of $47 thousand This was offset by a decrease in stock-based compensation of $0.3 million.

 

Research and development expenses increased by $0.8 million, or 99%, to $1.7 million for the three months ended September 30, 2021, from $0.9 million for the three months ended September 30, 2020. The increase was primarily attributable to an increase in pre-clinical activities related to Epoladerm of $0.6 million, Probudur of $12 thousand, VRP324 of $0.2 million, and AnQlar of $83 thousand. This was offset by a decrease in preclinical activity and milestone payments made for Envelta of $0.7 million.

 

As a result of the foregoing, the Company’s loss from operations for the three months ended September 30, 2021, was $3.2 million, compared to a loss from operations of $1.7 million for the three months ended September 30, 2020.

 

2

 

 

Nine Months Ended September 30, 2021 and 2020

 

Operating Expenses

 

General and administrative expenses increased by $2.5 million, or 107%, to $4.8 million for the nine months ended September 30, 2021, from $2.3 million for the nine months ended September 30, 2020. The primary reasons for the increase in general and administrative costs were (i) an increase in legal costs associated mainly with litigation efforts and legal costs associated with general corporate purposes of $1.9 million, (ii) an increase in insurance costs related to directors’ and officers’ insurance of $0.7 million, (iii) an increase in exchange listing fees of $0.1 million, and (iv) an increase in salaries and wages of $0.1 million. This was offset by a decrease in stock-based compensation of $0.3 million as compared to the prior period.

 

Research and development expenses increased by $1.9 million, or 160%, to $3.1 million for the nine months ended September 30, 2021, from $1.2 million for the nine months ended September 30, 2020. The increase was primarily attributable to (i) a $1.0 million milestone payment made to Nanomerics and preclinical activity of $0.1 million associated with AnQlar, (ii) increases in pre-clinical activity related to Epoladerm of $0.7 million, (iii) an increase in preclinical work in Probudur of $0.7 million, and (iv) a milestone payment of $0.2 million due to VRP324. This was slightly offset by a decrease of $0.7 million in pre-clinical activities associated with Envelta.

 

As a result of the foregoing, the Company’s loss from operations for the nine months ended September 30, 2021 was $7.9 million, compared to a loss from operations of $3.5 million for the nine months ended September 30, 2020.

 

Cash Flows

 

Cash used in operations was approximately $9.6 million for the nine months ended September 30, 2021, compared to approximately $1.2 million for the nine months ended September 30, 2020. The increase in cash used in operations was primarily the result of the increase in net loss, decrease in accounts payables balances, and an increase in prepaid insurance premiums and prepaid research and development.

 

Financing Activities

 

Cash provided by financing activities was $51.3 million during the nine months ended September 30, 2021, attributable primarily to net proceeds received from the Company’s initial public offering in February 2021 of $15.8 million and the underwritten offering in September 2021 of $37.0 million, after deducting underwriting discounts and offering expenses. These proceeds were offset by the repayment in full of the Company’s promissory note in the principal amount of $0.5 million in February 2021 and repayments of the Company’s promissory notes and PPP loan of an aggregate of $1.5 million. Cash provided by financing activities was $1.4 million during the nine months ended September 30, 2020, attributable to $1.4 million from the sale of 139,220 shares of the Company’s common stock as well as proceeds received from the PPP loan of $72,100.

 

At September 30, 2021, Virpax had cash of approximately $41.7 million.

 

About Virpax Pharmaceuticals

 

Virpax a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications is using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults. For more information, please visit www.virpaxpharma.com.

 

3

 

 

Forward-Looking Statement

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including but are not limited to, statements related to: expectations with regard to the timing of data events; the success, cost, and timing of our product candidates development activities and ongoing and planned pre-clinical trials; our estimates regarding expenses; and the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company’s operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

TABLES FOLLOW

 

4

 

 

VIRPAX Pharmaceuticals, Inc.

CONDENSED BALANCE SHEETS

 

   September 30,
2021		   December 31,
2020*		 
   (Unaudited)     
ASSETS        
Current assets        
Cash  $41,713,435   $54,796 
Prepaid expenses and other current assets   1,559,598    18,273 
Total current assets   43,273,033    73,069 
Deferred financing costs   —    392,337 
Total assets  $43,273,033   $465,406 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Accounts payable and accrued expenses  $1,811,809   $3,115,924 
Notes payable   -    543,990 
Total current liabilities   1,811,809    3,659,914 
Notes payable, net of current portion   -    21,590 
Related party notes payable   -    1,000,000 
Total long-term liabilities   -    1,021,590 
Total liabilities   1,811,809    4,681,504 
           
Commitments and contingencies          
           
Stockholders’ equity (deficit)          
Preferred stock, par value $0.00001, 10,000,000 shares authorized, no shares issued and outstanding   —    — 
Common stock, $0.00001 par value; 100,000,000 shares authorized, 11,715,182 shares issued and outstanding as of September 30, 2021; 3,145,153 shares issued and outstanding as of December 31, 2020   117    31 
Additional paid-in capital   60,047,385    6,431,715 
Accumulated deficit   (18,586,278)   (10,647,844)
Total stockholders’ equity (deficit)   41,461,224    (4,216,098)
Total liabilities and stockholders’ equity (deficit)  $43,273,033   $465,406 

 

*Derived from audited financial statements

 

5

 

 

VIRPAX Pharmaceuticals, Inc.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   For the Three
Months Ended
September 30,
2021		   For the Three
Months Ended
September 30,
2020		   For the Nine
Months Ended
September 30,
2021		   For the Nine
Months Ended
September 30,
2020		 
OPERATING EXPENSES                
General and administrative  $1,551,570   $810,674   $4,814,114   $2,321,509 
Research and development   1,698,204    851,780    3,089,769    1,187,333 
Total operating expenses   3,249,774    1,662,454    7,903,883    3,508,842 
Loss from operations   (3,249,774)   (1,662,454)   (7,903,883)   (3,508,842)
                     
OTHER (EXPENSE) INCOME                    
Interest expense   (28,892)   (45,709)   (93,640)   (129,600)
Other income (expense), net   62,922    -    59,089    4,000 
Loss before tax provision   (3,215,744)   (1,708,163)   (7,938,434)   (125,600)
Benefit from income taxes   —    —    —    — 
Net loss  $(3,215,744)  $(1,708,163)  $(7,938,434)  $(3,634,442)
                     
Basic and diluted net loss per share   (0.53)   (0.54)  $(1.59)  $(1.18)
Basic and diluted weighted average common stock outstanding   6,011,796    3,142,090    4,979,553    3,091,108 

 

6

 

 

VIRPAX Pharmaceuticals, Inc.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   For the Nine
Months Ended
September 30,
2021		   For the Nine
Months Ended
September 30,
2020		 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss  $(7,938,434)  $(3,634,442)
Adjustments to reconcile net loss to net cash used in operating activities:          
Non-cash interest expense   -    129,600 
Forgiveness of PPP loan   (61,816)   - 
Stock-based compensation   833,084    1,138,096 
Common stock issued in payment of consulting services and settlement of accounts payable   -    5,288 
Change in operating assets and liabilities:          
Prepaid expenses and other current assets   (999,685)   (12,873)
Accounts payable and accrued expenses   (1,453,418)   1,140,300 
Net cash used in operating activities   (9,620,269)   (1,234,031)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Repayment of notes payable   (503,764)   - 
Proceeds from the issuance of debt   -    72,100 
Proceeds from related party notes payable   100,000    - 
Repayment of related party notes payable   (1,100,000)     
Proceeds from the issuance of stock   -    1,376,900 
Offering costs related to secondary offering   (3,020,535)   - 
Proceeds from secondary offering of common stock   40,020,000    - 
Offering costs related to initial public offering   (2,216,793)   - 
Proceeds from initial public offering of common stock   18,000,000    - 
Net cash provided by financing activities   51,278,908    1,449,000 
           
Net change in cash   41,658,639    214,969 
Cash, beginning of period   54,796    41,536 
Cash, end of period  $41,713,435   $256,505 
           
Supplemental disclosure of cash and non-cash financing activities          
Cash paid for interest  $363,640   $— 
Cash paid for taxes  $—   $— 
Common stock issued in payment of consulting services and settlements of accounts payable  $—   $5,288 
Deferred financing costs, included in accounts payable and accrued expenses  $—   $176,391 
Debt issued in payment of consulting services and settlement of accounts payable  $—   $228,960 

 

Contact:

Christopher M. Chipman, CPA

Chief Financial Officer

cchipman@virpaxpharma.com

610-727-4597

 

Or

 

Betsy Brod

Affinity Growth Advisors

betsy.brod@affinitygrowth.com

212-661-2231

 

 

7

 

 

 EX-101.SCH 3 vrpx-20211115.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vrpx-20211115_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 vrpx-20211115_pre.xml XBRL PRESENTATION FILE XML 6 ea150252-8k_virpaxpharma_htm.xml IDEA: XBRL DOCUMENT 0001708331 2021-11-15 2021-11-15 iso4217:USD shares iso4217:USD shares 0001708331 false 8-K 2021-11-15 Virpax Pharmaceuticals, Inc. DE 001-40064 82-1510982 1055 Westlakes Drive Suite 300 Berwyn PA 19312 (610) 727-4597 false false false false Common Stock, par value $0.00001 per share VRPX NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 15, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 15, 2021
Entity File Number 001-40064
Entity Registrant Name Virpax Pharmaceuticals, Inc.
Entity Central Index Key 0001708331
Entity Tax Identification Number 82-1510982
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code (610)
Local Phone Number 727-4597
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol VRPX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://virpaxpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea150252-8k_virpaxpharma.htm ea150252ex99-1_virpaxpharma.htm vrpx-20211115.xsd vrpx-20211115_lab.xml vrpx-20211115_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea150252-8k_virpaxpharma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea150252-8k_virpaxpharma.htm" ] }, "labelLink": { "local": [ "vrpx-20211115_lab.xml" ] }, "presentationLink": { "local": [ "vrpx-20211115_pre.xml" ] }, "schema": { "local": [ "vrpx-20211115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VRPX", "nsuri": "http://virpaxpharma.com/20211115", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea150252-8k_virpaxpharma.htm", "contextRef": "From2021-11-15to2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://virpaxpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea150252-8k_virpaxpharma.htm", "contextRef": "From2021-11-15to2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001213900-21-059358-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-059358-xbrl.zip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end